$ALVO

Alvotech (ALVO) stock rose after Barclays upgraded its rating, citing a 59% upside potential. The company sells biosimilars in the U.S. and awaits approvals for pending files. Retail sentiment on Stocktwits shifted from bearish to bullish, with increased message volume. ALVO stock is up 6% year-to-date.

Alvotech's shares rose following a double upgrade from Barclays. The upgrade was based on various composite ratings, including valuation, EPS revisions, and visibility. The company's stock price increased by 1.59% on the day of the announcement.

Futures rise ahead of the Fed's expected 25bp rate hike, the first since 2023. Intel (INTC) shares jump 3% on reports of talks with SK Hynix for US memory chip production. JB Hunt (JBHT) falls 11% due to rising costs and an earnings warning. Alvotech (ALVO) rises 7% after a Barclays upgrade. The Fed's decision and economic data releases are key focuses for investors.

Analysts upgraded several companies: Needham upgraded Similarweb (SMWB) to Buy with a $11 target, Wolfe Research upgraded Paychex (PAYX) to Peer Perform, Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target, UBS upgraded Union Pacific (UNP) to Buy with a $339 target, and Barclays upgraded Alvotech (ALVO) to Overweight with a $8 target.

U.S. stock futures rose ahead of the Fed's rate decision. Alvotech gained 5.6% after a Barclays upgrade and price target increase. Beta Bionics fell 5.8% on a $150M offering. Expedia dropped 2.7% on an Underweight rating from Morgan Stanley. J.B. Hunt slid 9% after issuing an earnings warning. SK Hynix and Intel rose on reports of a potential U.S. memory-chip manufacturing deal.

Alvotech (ALVO) stock surged 5.6% in pre-market trading after Barclays upgraded it to Overweight, raising its price target to $8.00 from $4.00. The upgrade follows a favorable FDA inspection outcome and resubmitted biologics license applications, with approvals expected by December 2026. The broader market also showed gains, but Alvotech's move was company-specific.

Alvotech's ordinary shares and related securities are locked up from 15-JUN-2026 to 14-SEP-2026. Executive officers, directors, and certain securityholders agreed not to sell or transfer these shares without written consent. Alvotech is a biotechnology company focused on biosimilar medicines, with a pipeline targeting various therapeutic areas.

Alvotech (ALVO) announced FDA acceptance of its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio. The company reported a loss of $179.59 million and $1.14 billion in debt. Analysts expect earnings of $242.3 million by 2029, with 22.2% yearly revenue growth to $1.0 billion in sales. Regulatory outcomes and partner execution remain key risks.

Alvotech announced that the US FDA has accepted its Biologics License Application for AVT80, a proposed biosimilar to Entyvio. This development could impact Alvotech's market position and investor sentiment.

Alvotech (ALVO) rose 11.7% after announcing a licensing deal with Lotus Pharmaceutical for biosimilars AVT34 and AVT87, with up to $150M in payments. The company updated 2026 revenue guidance to $650–700M and reported a half-year net loss of $65.79M. Analysts note the deal expands market access but regulatory approvals remain key.